Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915569 | 0.91 | KDM4E (0.48) | HSP90AA1KDM4ETP53CYP3A4MAPT | |
| SCHEMBL20915444 | 0.91 | KDM4E (0.48) | HSP90AA1KDM4ETP53CYP3A4MAPT | |
| SCHEMBL20915245 | 0.91 | KDM4E (0.48) | HSP90AA1KDM4ETP53CYP3A4MAPT | |
| SCHEMBL20915445 | 0.91 | KDM4E (0.48) | HSP90AA1KDM4ETP53CYP3A4MAPT | |
| SCHEMBL20936399 | 0.91 | KDM4E (0.48) | HSP90AA1KDM4ETP53CYP3A4MAPT | |
| SCHEMBL20936408 | 0.91 | KDM4E (0.48) | HSP90AA1KDM4ETP53CYP3A4MAPT | |
| SCHEMBL18978339 | 0.86 | MEN1 (0.47) | CA1CA2HSP90AA1CNR1CCR2 | |
| SCHEMBL4638149 | 0.82 | CCR2 (0.40) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL10598507 | 0.79 | HSP90AA1 (0.41) | CA1CA2HSP90AA1ALDH1A1HDAC3 | |
| SCHEMBL16925399 | 0.78 | MAPT (0.38) | KDM4ETP53CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4238334-B2 | — | — | 2009-03-18 | — | — | JP | claimed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | claimed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | claimed |
| JP-2001500149-A | — | — | 2001-01-09 | — | — | JP | claimed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | claimed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | claimed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-1028716-A1 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999044602-A1 | INFLAMMATORY CELL INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999040910-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| US-5691382-A | ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | CA1 3618/4885CA2 4418/4885HSP90AA1 1319/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | CA1 3618/4885CA2 4418/4885HSP90AA1 1319/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | CA1 3618/4885CA2 4418/4885HSP90AA1 1319/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | CA1 3618/4885CA2 4418/4885HSP90AA1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.